Overview

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties.

Please see Terms of Use for this website.

E-mail Alerts

Sign up here to receive press releases via email.

Receive E-mail AlertsE-mail Alerts
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
Apr 22, 2014Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
- Conference Call and Webcast at 4:30 p.m. Eastern Time - SEATTLE, April 22, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). A... 
Printer Friendly Version
Mar 05, 2014Cell Therapeutics to Present at the 26th Annual ROTH Conference
SEATTLE, March 5, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA. The presentation will be webcast live and available for replay from the Cell Therapeutics' website Investors section at www.celltherapeutics.com. About Cell Therapeutics Cell Therapeutics (NASDAQ and MTA: CTIC) is a... 
Printer Friendly Version
Mar 04, 2014Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
- 2014 Priorities: Complete and Report Top-line Results of First Pacritinib Phase 3 and Drive EU Sales of PIXUVRI - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, March 4, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013. "2013 was a transformational year for CTI, as we entered into a worldwide license agreement with Baxter International t... 
Printer Friendly Version
Mar 03, 2014CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300 patient... 
Printer Friendly Version
Feb 27, 2014NICE Publishes Final Guidance on PIXUVRI® (pixantrone)
- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE, Feb. 27, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final g... 
Printer Friendly Version
Feb 25, 2014Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014
- Conference Call and Webcast at 4:30 p.m. Eastern Time - SEATTLE, Feb. 25, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 ... 
Printer Friendly Version
Feb 03, 2014Cell Therapeutics Appoints Karen Ignagni to Board of Directors
SEATTLE, Feb. 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately. Ms. Ignagni currently serves as President and Chief Executive Officer of America's Health Insurance Plans (AHIP), which is the trade association representing U.S. health plans, serving members that provide healthcare, long-term care, dental and disability benefits to more than 200 million Americans. "We are d... 
Printer Friendly Version
Jan 30, 2014CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia
- Trial Sponsored by Cardiff University and Supported by Cancer Research UK - SEATTLE, Jan. 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prog... 
Printer Friendly Version
Jan 28, 2014Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer
SEATTLE, Jan. 28, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio™ ) as maintenance therapy in ovarian cancer. "Although initial treatment is effective in putting this disease in remission, there is a high relapse rate for patients with ovarian cancer and there ar... 
Printer Friendly Version
Jan 14, 2014Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
SEATTLE, Jan. 14, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced a corporate update for 2014 in addition to an overview of recent progress for its drug portfolio. "We ended 2013 and have entered 2014 with a series of successes, including a global strategic partnership for pacritinib, positive reimbursement rulings in England/Wales and Germany for PIXUVRI, the reacquisition of rights to PIXUVRI and Opaxio in order to allow us to more efficiently move ... 
Printer Friendly Version
Jan 13, 2014Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI®) and paclitaxel poliglumex (Opaxio™). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date.  Upon the effective date of termination, CTI will regain all rights that had... 
Printer Friendly Version
Jan 06, 2014PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from NICE
- PIXUVRI Deemed Cost Effective for Patients with Multiply Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - SEATTLE, Jan. 6, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the United Kingdom (UK), has issued its Final Appraisal Determination (FAD) for P... 
Printer Friendly Version
Jan 02, 2014Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
SEATTLE, Jan. 2, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival, and is under developme... 
Printer Friendly Version
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue